Juno Therapeutics (JUNO) Shares are Down -0.27%

Juno Therapeutics (JUNO) : During the past 4 weeks, traders have been relatively bearish on Juno Therapeutics (JUNO), hence the stock is down -32.54% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.88% relative to the S&P 500. The 4-week change in the price of the stock is -27.99% and the stock has fallen -0.27% in the past 1 week.

Juno Therapeutics (NASDAQ:JUNO): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $28.94 and $28.50 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $29.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $29.13, notching a gain of 1.04% for the day. The total traded volume was 1,046,295 . The stock had closed at $28.83 on the previous day.


The stock has recorded a 20-day Moving Average of 14.87% and the 50-Day Moving Average is 25.03%. Juno Therapeutics Inc. has dropped 34.51% during the last 3-month period . Year-to-Date the stock performance stands at -33.75%.

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *